As signaled in the second-quarter earnings call, AbbVie's received approval in Japan for Viekirax, the oral interferon- and ribavirin-free combination therapy for hepatitis C, establishing an important beachhead for the company in Asia's top reimbursement market.
China Daily posted an interview with Bill Gates, co-founder of Microsoft and co-chair of the Bill & Melinda Gates Foundation, who lauded the country's efforts to build on reforms that have transformed access to healthcare services in the world's most populous country.
Merck, building on the success of its diabetes blockbuster Januvia, won a first global approval for a long-acting form of the drug, convincing Japanese regulators to approve its new weekly product.
As the FDA again reviews its guidance on disclosing prescription drug risk information, two New England Journal of Medicine articles are suspicious that new guidelines would change much for patients.
Hillary Clinton's plan to take away drugmakers' advertising tax deductions gets a resounding "no" from ad industry trade groups. While the ad executives aren't taking a stance on the rest of Clinton's drug-pricing plan, the advertising proposal gets a thumbs down.
The FDA is cracking down on Pathway Genomics for improperly marketing its liquid biopsy test, a couple of weeks after the company rolled out its product directly to consumers for the early detection of cancer.
Within weeks of getting a conditional nod to resume shipments from two of the company's manufacturing units in India, Canada's largest generics maker has recalled 117,644 bottles of cevimeline hydrochloride capsules in the U.S. that were made by the company's Indian arm, Apotex Research, the Business Standard newspaper reports.
The research arm of Sun Pharmaceutical Industries has seen its license for epilepsy drug Elepsia XR revoked by the U.S. FDA because of manufacturing violations at its production site, dealing a blow to its aims of moving beyond generics.
Two years after the FDA's shock rejection of Novo Nordisk's next-generation insulin, the Danish drugmaker has convinced U.S. regulators to change their tune, setting the stage for a market duel with Sanofi.
In an effort aimed at encouraging earlier diagnosis and even potentially prevention for Type 1 diabetes, the JDRF and the American Diabetes Association have published a new evaluation of the presymptomatic staging of Type 1 diabetes.